Incretin-based治疗2型糖尿病:审查直接比较的有效性、安全性和病人满意度。
文章的细节
-
引用
复制到剪贴板 -
罗素年代
Incretin-based治疗2型糖尿病:审查直接比较的有效性、安全性和病人满意度。
Int中国制药。2013年4月,35 (2):159 - 72。doi: 10.1007 / s11096 - 012 - 9729 - 9。Epub 2012年12月22日。
- PubMed ID
-
23263796 (在PubMed]
- 文摘
-
背景:临床试验比较incretin-based therapies-glucagon-like peptide-1受体受体激动剂(exenatide-twice日报,一旦每周和每天换一次liraglutide)和dipeptidyl peptidase-4抑制剂(vildagliptin, sitagliptin saxagliptin和linagliptin)——安慰剂和口服抗糖尿病的药物表明,这些治疗方法有效地控制glycaemia,低血糖的风险较低。Glucagon-like peptide-1受体受体激动剂与减肥和降低收缩压,虽然dipeptidyl peptidase-4 weight-neutral抑制剂。在此基础上,国家健康和临床研究所建议在2型糖尿病患者使用这些代理来说,超重和/或低血糖是有问题的。评审的目的:本文旨在帮助决策选择和使用时incretin-based治疗2型糖尿病。方法:搜索或MEDLI必威国际appNE和Cochrane临床试验数据库,执行有限的人类临床试验,使用搜索条件“exenatide liraglutide或vildagliptin sitagliptin,或者saxagliptin linagliptin”。摘要在最近的美国糖尿病协会和欧洲糖尿病研究协会的会议也被搜查了。必威国际app十八岁的临床试验直接比较incretin-based疗法被确定。结果:Glucagon-like peptide-1受体受体激动剂显著降低糖化血红蛋白和重量大于dipeptidyl peptidase-4抑制剂,对重量有中性的影响。处理间差异是临床上重要的。胃肠道副作用更频繁了glucagon-like peptide-1受体受体激动剂与dipeptidyl peptidase-4抑制剂。 Comparisons between glucagon-like peptide-1 receptor agonists and between dipeptidyl peptidase-4 inhibitors showed that differences within the available agents in the two sub-classes are small. Greater treatment satisfaction was reported with glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors. CONCLUSION: Glucagon-like peptide-1 receptor agonists achieve greater glycated hemoglobin reductions than dipeptidyl peptidase-4 inhibitors, with concomitant weight loss. Probably due to the greater efficacy of glucagon-like peptide-1 receptor agonists, patient satisfaction is greater with these agents compared with dipeptidyl peptidase-4 inhibitors despite injectable versus oral administration and more frequent gastrointestinal side effects with the agonists.
DrugBank数据引用了这篇文章
- 药物